乳がんコアニードルバイオプシー市場規模、シェア、動向分析レポート：技術別、最終用途別、地域別、セグメント予測、2025年～2030年

乳がんコアニードル生検市場の成長と動向

Grand View Research, Inc.の最新レポートによると、乳がんコアニードル生検の世界市場規模は2030年までに11億5,000万米ドルに達すると推定され、2025～2030年にかけてCAGR 4.6％で成長する見込みです。

市場成長の主要要因は、乳がんの有病率の増加、定期的なマンモグラフィ検診の推奨の普及、個人の意識の高まり、このセグメントで実施された広範な調査研究などです。これらの要因が総合的に乳がんコアニードル生検の需要増加と採用に寄与しており、今後数年間の著しい成長への道を開いています。

さらに、画像技術や生検技術の絶え間ない進歩も産業の拡大に寄与しています。早期発見と診断が患者の予後改善に果たす重要な役割に対する認識が高まっています。コアニードル生検は、従来の開腹手術による生検と比較して、侵襲性の低減、回復時間の短縮、費用対効果などの明確な利点を記載しています。

早期発見・診断の需要が高まり続ける中、乳がんコアニードル生検市場は大きな成長が見込まれています。このセグメントにおける革新的な研究の最近の例としては、スペインのIMIM（Hospital del Mar Medical Research Institute）の研究者が2022年にEuropean Radiology誌に発表した調査結果のように、病変の可視化にMRI技術を利用した造影マンモグラフィ誘導乳房生検の使用が挙げられます。

COVID-19の大流行は、乳がんコアニードル生検市場における課題であると同時に新たな機会ももたらしました。必要のない処置の遅れは、診断率の低下とコアニードル生検の需要の減少につながりました。しかし、パンデミックは早期発見の重要性を強調し、医療提供者に検診と生検を優先させるようにし、その結果需要が復活しました。

乳がんコアニードル生検市場レポートハイライト

• 超音波ベースの乳房生検セグメントは、2024年に41.9%の最大の売上シェアを占めました。このセグメントの優位性は、超音波ガイド下生検の顕著な利点による嗜好の高まりに起因しています。
• 病院＆診断ラボセグメントは、2024年に60.0％の最高収益シェアを獲得しました。
• 学術・研究機関セグメントは、乳がんコアニードル生検産業において2025～2030年にかけてCAGR 4.4%の飛躍的な成長が予測されています。
• 北米の乳がんコアニードル生検産業は、2024年に46.26％の売上シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 乳がんコアニードル生検市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 乳がんコアニードル生検市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 乳がんコアニードル生検市場：技術別、推定・動向分析

• 技術市場シェア、2024年と2030年
• セグメントダッシュボード
• 技術による世界の乳がんコアニードル生検市場の展望
• 2018～2030年の市場規模と予測と動向分析
  • MRIによる乳房生検
  • 超音波による乳房生検
  • マンモグラフィー（定位的）乳房生検
  • CTによる乳房生検
  • その他の画像ベースの乳房生検

第5章 乳がんコアニードル生検市場： 最終用途別、推定・動向分析

• 最終用途市場シェア、2024年と2030年
• セグメントダッシュボード
• 最終用途による世界の乳がんコアニードル生検市場の展望
• 2018～2030年の市場規模と予測と動向分析
  • 病院＆診断ラボ
  • 製薬・バイオテクノロジー企業
  • 学術研究機関

第6章 乳がんコアニードル生検市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業の市場シェア分析、2024年
  • Intact Medical Corporation
  • Ethicon Surgical Technologies
  • Gallini SRL
  • Leica Biosystems Nussloch GmbH
  • Hologic, Inc
  • Argon Medical Devices
  • Encapsule Medical Devices LLC
  • Cook Medical Incorporated
  • Becton, Dickinson and Company
  • CR Bard, Inc.

List of Tables

• Table 1 List of abbreviations
• Table 2 Global breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 3 Global breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 4 Global breast cancer core needle biopsy market, by region, 2018 - 2030 (USD Million)
• Table 5 North America breast cancer core needle biopsy market, by country, 2018 - 2030 (USD Million)
• Table 6 North America breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 7 North America breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 8 U.S. breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 9 U.S. breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 10 Canada breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 11 Canada breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 12 Mexico breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 13 Mexico breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 14 Europe breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
• Table 15 Europe breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 16 Europe breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 17 UK breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 18 UK breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 19 Germany breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 20 Germany breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 21 France breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 22 France breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 23 Italy breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 24 Italy breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 25 Spain breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 26 Spain breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 27 Denmark breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 28 Denmark breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 29 Sweden breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 30 Sweden breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 31 Norway breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 32 Norway breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 33 Asia Pacific breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 36 Japan breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 37 Japan breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 38 China breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 39 China breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 40 India breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 41 India breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 42 Australia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 43 Australia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 44 Thailand breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 45 Thailand breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 46 South Korea breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 47 South Korea breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 48 Latin America breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
• Table 49 Latin America breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 50 Latin America breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 51 Brazil breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 52 Brazil breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 53 Argentina breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 54 Argentina breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 55 Middle East & Africa breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa breast cancer core needle biopsy, by technology, 2018-2030, (USD
• Table 57 Middle East & Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 58 South Africa breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 59 South Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 60 Saudi Arabia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 62 UAE breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 63 UAE breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 64 Kuwait breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 65 Kuwait breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 breast cancer core needle biopsy market segmentation
• Fig. 8 Market snapshot, 2024
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 13 Porter's Five Forces analysis
• Fig. 14 Global breast cancer core needle biopsy market: Technology movement analysis
• Fig. 15 Global breast cancer core needle biopsy market, for MRI-based breast biopsy, 2018 - 2030 (USD Million)
• Fig. 16 Global breast cancer core needle biopsy market, for ultrasound-based breast biopsy, 2018 - 2030 (USD Million)
• Fig. 17 Global breast cancer core needle biopsy market, for mammography-based (stereotactic) breast biopsy, 2018 - 2030 (USD Million)
• Fig. 18 Global breast cancer core needle biopsy market, for CT-based breast biopsy, 2018 - 2030 (USD Million)
• Fig. 19 Global breast cancer core needle biopsy market, for other image-based breast biopsy, 2018 - 2030 (USD Million)
• Fig. 20 Global breast cancer core needle biopsy market: End use movement analysis
• Fig. 21 Global breast cancer core needle biopsy market, for hospitals & diagnostic laboratories, 2018 - 2030 (USD Million)
• Fig. 22 Global breast cancer core needle biopsy market, for pharmaceutical & biotechnology companies, 2018 - 2030 (USD Million)
• Fig. 23 Global breast cancer core needle biopsy market, for academic & research institutes, 2018 - 2030 (USD Million)
• Fig. 24 Regional marketplace: Key takeaways
• Fig. 25 Regional outlook, 2024 & 2030
• Fig. 26 Global breast cancer core needle biopsy market: Region movement analysis
• Fig. 27 North America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 28 U.S. breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 29 Canada breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 30 Mexico breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 31 Europe breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 32 Germany breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 33 UK breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 34 France breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 35 Italy breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 36 Spain breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 37 Denmark breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 38 Sweden breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 39 Norway breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 40 Asia Pacific breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 41 Japan breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 42 China breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 43 India breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 44 Australia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 45 South Korea breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 46 Thailand breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 47 Latin America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 48 Brazil breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 49 Argentina breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 50 Middle East and Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 51 South Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 52 Saudi Arabia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 53 UAE breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 54 Kuwait breast cancer core needle biopsy market, 2018 - 2030 (USD Million)

Breast Cancer Core Needle Biopsy Market Growth & Trends:

The global breast cancer core needle biopsy market size is estimated to reach USD 1.15 billion by 2030, registering to grow at a CAGR of 4.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights:

• The ultrasound-based breast biopsy segment accounted for the largest revenue share of 41.9% in 2024. The segment dominance can be attributed to the growing preference for ultrasound-guided biopsies due to their notable advantages.
• The hospitals & diagnostic laboratories segment captured the highest revenue share of 60.0% in 2024.
• The academic & research institutes segment is predicted to grow at an exponential CAGR of 4.4% from 2025 to 2030 in the breast cancer core needle biopsy industry.
• North America breast cancer core needle biopsy industry dominated and accounted for a 46.26%of revenue share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. End use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Breast Cancer Core Needle Biopsy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing prevalence of breast cancer
    • 3.2.1.2. Advancement in imaging technologies and biopsy techniques
    • 3.2.1.3. Rising inclination towards minimally invasive procedures
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of core needle biopsy procedures
    • 3.2.2.2. Limited expertise and training
• 3.3. Breast Cancer Core Needle Biopsy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Breast Cancer Core Needle Biopsy Market: Technology Estimates & Trend Analysis

• 4.1. Technology Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Breast Cancer Core Needle Biopsy Market by Technology Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. MRI-Based Breast Biopsy
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.2. Fermentation Ultrasound-Based Breast Biopsy
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Mammography-Based (Stereotactic) Breast Biopsy
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. CT-Based Breast Biopsy
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Other Image-Based Breast Biopsy
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Breast Cancer Core Needle Biopsy Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Breast Cancer Core Needle Biopsy Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Hospitals & Diagnostic Laboratories
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 5.4.2. Pharmaceutical & Biotechnology companies
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Academic & Research Institutes
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Breast Cancer Core Needle Biopsy Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Target Disease Prevalence
    • 6.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Target Disease Prevalence
    • 6.5.2.4. Competitive scenario
    • 6.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Target Disease Prevalence
    • 6.5.3.4. Competitive scenario
    • 6.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Target Disease Prevalence
    • 6.6.1.4. Competitive scenario
    • 6.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Target Disease Prevalence
    • 6.6.2.4. Competitive scenario
    • 6.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Target Disease Prevalence
    • 6.6.3.4. Competitive scenario
    • 6.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Target Disease Prevalence
    • 6.6.4.4. Competitive scenario
    • 6.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Target Disease Prevalence
    • 6.6.5.4. Competitive scenario
    • 6.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Target Disease Prevalence
    • 6.6.6.4. Competitive scenario
    • 6.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Target Disease Prevalence
    • 6.6.7.4. Competitive scenario
    • 6.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Target Disease Prevalence
    • 6.6.8.4. Competitive scenario
    • 6.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Target Disease Prevalence
    • 6.7.1.4. Competitive scenario
    • 6.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Target Disease Prevalence
    • 6.7.2.4. Competitive scenario
    • 6.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Target Disease Prevalence
    • 6.7.3.4. Competitive scenario
    • 6.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Target Disease Prevalence
    • 6.7.4.4. Competitive scenario
    • 6.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Target Disease Prevalence
    • 6.7.5.4. Competitive scenario
    • 6.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Target Disease Prevalence
    • 6.7.6.4. Competitive scenario
    • 6.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Target Disease Prevalence
    • 6.8.1.4. Competitive scenario
    • 6.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Target Disease Prevalence
    • 6.8.2.4. Competitive scenario
    • 6.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Target Disease Prevalence
    • 6.9.1.4. Competitive scenario
    • 6.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Target Disease Prevalence
    • 6.9.2.4. Competitive scenario
    • 6.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Target Disease Prevalence
    • 6.9.3.4. Competitive scenario
    • 6.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Target Disease Prevalence
    • 6.9.4.4. Competitive scenario
    • 6.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company market share analysis, 2024
  • 7.3.2. Intact Medical Corporation
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Ethicon Surgical Technologies
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Gallini SRL
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Leica Biosystems Nussloch GmbH
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Hologic, Inc
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Argon Medical Devices
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Encapsule Medical Devices LLC
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Cook Medical Incorporated
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Becton, Dickinson and Company
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. C.R. Bard, Inc.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives